Treatments
Overview
Clinics
Overview
A once-weekly injection pen with semaglutide, prescribed only after a UK clinician reviews your health.
Takes about two minutes · cancel any time
UK-registered pharmacy, dispensed in the UK
Prescribed only after a clinician review
Next-day weekday delivery in discreet packaging
DOSING
6 strengths, one step at a time. From £139 a month.
Weeks 1 to 4
£139
a month
Weeks 5 to 8
£179
a month
Weeks 9 to 12
£187
a month
Weeks 13 to 16 or longer
£237
a month
Week 17 onwards
£287
a month
Week 21 onwards
£328
a month
Wegovy is a once-weekly injection licensed for weight management. The active ingredient is semaglutide. It works on the GLP-1 appetite hormone pathway, the same pathway targeted by other established weight-loss medicines.
By copying that signal it helps steady appetite, slow digestion and improve blood sugar control. It has the longest real-world track record of the weekly injections currently available in the UK.
In a 68-week study people on the highest dose lost an average of 14.9% of their body weight when semaglutide was combined with lifestyle support.
HOW IT WORKS
Clinician-led treatment works with the body’s own appetite signals rather than against them, which is why the weight tends to stay off while you are on it.
You feel less pulled towards food between meals, so choices get easier.
Your stomach empties more slowly, so smaller meals still satisfy.
The constant background thinking about food tends to settle down.
Fewer energy dips through the day, which means fewer hunger spikes.
ONE PATHWAY
Wegovy copies one hormone pathway. It is the same pathway used by other established weight-loss medicines, and the one with the longest real-world safety record in the UK.
Slows stomach emptying, helping you feel fuller for longer
Reduces appetite and the drive to eat
Helps reduce food cravings and snacking
Helps control the rise in blood sugar after eating
Both are weekly injections and both quiet appetite. The difference is how many gut hormone pathways each one copies — semaglutide copies one, tirzepatide copies two — and that gap shows up in the trial figures.
Semaglutide · GLP-1 only
The established single-pathway option
Tirzepatide · GLP-1 + GIP
The dual-pathway option, higher average loss
Average weight loss in trials
14.9% at 2.4mg
20.9% at 15mg
Hormone pathways copied
One — GLP-1
Two — GLP-1 and GIP
What the second pathway adds
Not applicable
GIP appears to improve how the body handles fat and blood sugar alongside appetite
Higher-dose option
2.4mg standard, 7.2mg prescriber-led
15mg is the top licensed dose
Typical tolerance settling in
Often settles more easily for people sensitive to nausea
More loss, but dose increases can be harder to tolerate
Track record in the UK
Longer real-world use, larger body of published data
Newer, with strong trial data from 2022 onwards
USING IT
A dial-a-dose FlexTouch pen with a new needle each week, four doses per pen. Three stages, start to finish.



Prepare
Set the dose
Stomach. Easiest to reach. Stay at least 5cm clear of your belly button.
Upper leg. The front and outer part, halfway between hip and knee.
Upper arm. Fine if someone else is doing it for you, awkward on your own.
Inject and bin
Keep unopened pens in the fridge between 2 and 8 degrees. Once you have started a pen, keep it for up to 6 weeks, in the fridge or below 30 degrees, with the cap on. Never freeze it. Read the patient information leaflet
SAFETY
Side effects are common when you start any new medicine. Most are mild and ease off as your body settles, and going up more slowly helps more than anything else.
Like all medicines, Wegovy has side effects. In the STEP trials, nausea, diarrhoea and constipation were common. They were usually mild, worst in the first week after a dose increase, and faded within a few days as the body settled.
THE MOST COMMON WEGOVY SIDE EFFECTS INCLUDE
These are usually worst in the first week after a dose increase and settle within a few days. Going up more slowly helps more than anything else.
WE WILL NOT PRESCRIBE IT IF
Rare but serious — get medical help straight away for severe tummy pain spreading to your back, yellow skin or eyes, swelling of the face, lips or throat, trouble breathing, or vomiting you cannot stop.
Climb the doses slowly, use smaller plates, stop when comfortable rather than full, keep fatty and fried food light for a few days after a step up, and drink steadily. Most sickness and gut upset fades within a week.
Constipation, reflux, bloating, dizziness and tiredness can also happen. Speak to the clinical team if a symptom is lasting, worsening, or getting in the way of your usual routine.
Message the clinical team on WhatsApp, seven days a week. We can tell you what needs attention and what usually settles on its own.
MESSAGE YOUR CLINICAL TEAM
Cancel anytime · No lock-in · No consultation fee

YOUR PROJECTION
Put in your details to see a personalised trajectory over 68 weeks, based on Wegovy trial outcomes.
Your BMI
QUESTIONS
Most people regain some weight after stopping. Appetite returns as the medicine clears, so stopping is usually best planned with a prescriber.
Appetite usually changes within the first one to two weeks. Weight loss typically becomes clear from around the third month and continued steadily for about 68 weeks in trials.
Average weight loss was 14.9% of body weight over 68 weeks on the 2.4mg dose in STEP 1. Individual results vary.
Some lean tissue is lost with any substantial weight loss. Adequate protein and resistance training help preserve muscle.
Wegovy acts on GLP-1, while Mounjaro acts on GLP-1 and GIP. Trial averages and tolerability differ, so the right choice depends on clinical judgement.
They contain the same active ingredient, semaglutide, but are licensed for different uses and are not interchangeable.
Yes, for best results. All the trial outcomes were achieved with diet and exercise support alongside the medicine. Because portions become much smaller, food quality matters more: adequate protein at each meal, plenty of vegetables and fibre, and enough fluid help protect muscle and reduce constipation. Very fatty or heavily processed meals tend to worsen nausea.
Wegovy is licensed in the UK and considered safe for most eligible adults when prescribed and monitored by a registered clinician.
Smaller, lower-fat meals, steady fluids and holding the current dose for longer usually help. Persistent or severe sickness should be reported.
There is no absolute contraindication, but alcohol is best limited because it can worsen nausea and reflux.
No. Dose increases are optional and led by clinical review. Many people remain on a lower effective dose.
If fewer than five days have passed, take it when remembered. If more than five days have passed, skip it and continue on the normal day.
Yes, provided there are at least three days between injections.
Yes. A UK-registered prescriber can assess your history, height and weight remotely and arrange follow-up.
Pens are sent by tracked courier in insulated, temperature-controlled, plain packaging.
Yes. Semaglutide is prescription-only and must be supplied after a clinician assessment.
Yes. Semaglutide is not a fixed course and treatment can be stopped at any point, ideally with a maintenance plan.
Prices vary by dose. On this page they begin at £139 per month and include the clinician review, pen, needles, sharps bin, delivery and support.
Reviewed by · 4 November 2026 · Next review November 2027
Pharmacist Independent Prescriber · GPhC 2075913
Prescription, clinician review and next-day weekday delivery to your door.
✓ Prescribed only after a clinician review
Wegovy · 0.25mg · from £139/mo
from £139 a month
Quick self-check
Three quick questions. Takes under a minute.
Question 1 of 3
Your answers are confidential and reviewed by UK-registered clinicians.
WEIGHT LOSS
Established pen
Advanced pen
Daily oral — needle-free
Daily tablet — no timing rules
LONDON LOCATIONS
Marylebone · W1G · £250
Marylebone · W1H · £150
♢ UK-registered clinicians · Next-day weekday delivery